Amesanar is under clinical development by RHEACELL and currently in Phase III for Epidermolysis Bullosa. According to GlobalData, Phase III drugs for Epidermolysis Bullosa does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Amesanar LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amesanar overview
Amesanar (Allogeneic ABCB5-positive mesenchymal stem cells) is acting on chronic non-healing wounds in humans. It is formulated as solution for subcutaneous route of administration. Amesanar is indicated for chronic venous ulcers on the basis of an existing chronic venous insufficiency (CVI).
See Also:
Allo-APZ2 is under development for the treatment of chronic venous ulcer (CVU), diabetic foot ulcer (DFU) and recessive dystrophic epidermolysis bullosa (RDEB). It is administered through intramuscular, intravenous and cutaneous routes. The therapeutic candidate comprises of skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors (allogeneic ABCB5-positive stem cells). It acts by targeting ATP-binding cassette sub-family B member 5 (ABCB5).
It was also under development for the treatment of acute kidney injury, acute-on chronic liver failure (ACLF) and peripheral artery occlusive disease.
RHEACELL overview
RHEACELL is a biopharmaceutical company that develops stem cell based drugs targeting inflammatory and degenerative diseases. It is investigating allo-APZ2 (allogeneic ABCB5-positive stem cells) against chronic venous ulcers (CVU), diabetic foot ulcers (DFU), recessive dystrophic epidermolysis bullosa (RDEB), and acute on chronic liver failure (ACLF). The company also evaluating APZ2 (autologous ABCB5-positive stem cells) for CVU; and LSC2 (limbal stem cells), a regenerative medicine to treat limbal stem cell deficiency (LSCD). RHEACELL utilizes ABCB5-positive (ABCB5+) mesenchymal stem cells platform technology to develop its drugs. It works in collaboration with scientists and clinicians. RHEACELL is headquartered in Heidelberg, Baden-Wurttemberg, Germany.
For a complete picture of Amesanar’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
